Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 9-14

  Piñana, José Luis ^a,b   Martino, Rodrigo ^a   Barba, Pere ^a,c   Bellido Casado, Jesús ^d   Valcárcel, David ^a,c   Sureda, Anna ^a   Briones, Javier ^a   Brunet, Salut ^a   Rodriguez Arias, José Manuel ^d   Casan, Pere ^d   Sierra, Jorge ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Hospital Manises   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CARBON MONOXIDE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; HEMOGLOBIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT VERSUS HOST REACTION; HUMAN; INFECTIOUS PNEUMONIA; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESIDUAL VOLUME; RETROSPECTIVE STUDY; TOTAL LUNG CAPACITY;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG DISEASES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RESPIRATORY FUNCTION TESTS; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84155167032     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22183     Document Type: Article

References (46)

1. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 2004; 104: 961-968.
2. Xhaard A, Porcher R, Chien JW, et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 2008; 22: 2062-2069.
3. Guilfoyle R, Demers A, Bredeson C, et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43: 133-139.
4. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 2007; 110: 4606-4613.
5. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
6. Barba P, Piñana JL, Martino R, et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: The flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant 2010; 16: 413-420.
7. Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009; 23: 1131-1138.
8. Parimon T, Madtes DK, Au DH, et al. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med 2005; 172: 384-390.
9. Clark JG, Schwartz DA, Flournoy N, et al. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987; 107: 648-656.
10. Badier M, Guillot C, Delpierre S, et al. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant 1993; 12: 457-461.
11. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407-414.
12. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208-214.
13. Gore EM, Lawton CA, Ash RC, Lipchik RJ. Pulmonary function changes in long-term survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys 1996; 36: 67-75.
14. Chien JW, Martin PJ, Flowers ME, et al. Implications of early airflow decline after myeloablative allogeneic stem cell transplantion. Bone Marrow Transplant 2004; 33: 759-764.
15. Horak DA, Schmidt GM, Zaia JA, et al. Pretransplant pulmonary function predicts cytomegalovirus-associated interstitial pneumonia following bone marrow transplantation. Chest 1992; 102: 1484-1490.
16. Ho VT, Weller E, Lee SJ, et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 223-229.
17. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998; 16: 3796-3802.
18. Chien JW, Maris MB, Sandmaier BM, et al. Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 288-296.
19. Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest 1992; 101: 1257-1264.
20. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 2: 577-584.
21. Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results of a prospective multicentre study. Br J Haematol 2001; 115: 653-659.
22. Pérez-Simón JA, Díez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005; 130: 394-403.
23. Martino R, Pérez-Simón JA, Moreno E, et al. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. Biol Blood Marrow Transplant 2005; 11: 437-447.
24. Piñana JL, Martino R, Barba P, et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: Single-centre experience. Bone Marrow Transplant 2009; 45: 534-542.
25. Martino R, Piñana JL, Parody R, et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant 2009; 44: 749-756.
26. Quanjer PH, Tammeling GJ, Pederson OF, et al. Report working party standardization of lung function tests European Community for Steel and Coal. Official statement of the European Respiratory Society. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6: 5-40.
27. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
28. Sanchis J, Casan P, Castillo J, et al. Normativa para la practica de la espirometria forzada. Arch Bronconeumol 1989; 25: 132-142.
29. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
30. Becklake M, Crapo RO, Buist AS. Lung function testing: Selection of reference values and interpretative strategies. An official statement of the American Thoracic Society. Am Rev Respir Dis 1991; 144: 1202-1218.
31. Chien JW, Madtes DK, Clark JG. Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35: 429-435.
32. Clark JG, Hansen JA, Hertz MI, et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147: 1601-1606.
33. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
34. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001; 28: 909-915.
35. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001-1011.
36. White AC, Terrin N, Miller KB, Ryan HF: Impaired respiratory and skeletal muscle strength in patients prior to hematopoietic stem-cell transplantation. Chest 2005; 128: 145-152.
37. Savani BN, Montero A, Srinivasan R, et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1261-1269.
38. Krowka MJ, Rosenow EC, Hoagland HC: Pulmonary complications of bone marrow transplantation. Chest 1985; 87: 237-246.
39. Cordonnier C, Bernaudin JF, Bierling P, et al. Pulmonary complications occurring after allogeneic bone marrow transplantation. A study of 130 consecutive transplanted patients. Cancer 1986; 58: 1047-1054.
40. Breuer R, Lossos IS, Berkman N, Or R. Pulmonary complications of bone marrow transplantation. Respir Med 1993; 87: 571-579.
41. Lee HG, Park BB, Peck KR, et al. Pulmonary complications after hematopoietic stem cell transplantation. J Korean Med Sci 2006; 21: 406-411.
42. Patriarca F, Skert C, Bonifazi F, et al. Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica 2006; 91: 1268-1272.
43. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1072-1078.
44. Horak DA, Schmidt GM, Zaia JA, et al. Pretransplant pulmonary function predicts cytomegalovirus-associated interstitial pneumonia following bone marrow transplantation. Chest 1992; 102: 1484-1490.
45. Ghalie R, Szidon JP, Thompson L, et al. Evaluation of pulmonary complications after bone marrow transplantation: The role of pretransplant pulmonary function tests. Bone Marrow Transplant 1992; 10: 359-365.
46. Ramirez-Sarmiento A, Orozco-Levi M, Walter EC, et al. Influence of pretransplantation restrictive lung disease on allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant 2010; 16: 199-206.